GlassScriptPhysician profile
Mary Staton
NPI 1154528313
$4,557.90
in general payments reported to CMS, 2019-2025
29 companies · $970 in 2025
The $970 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $32.73 · 2022: $123 · 2023: $1,976 · 2024: $1,456 · 2025: $970.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,384 · Travel and Lodging: $564 · Long Term Medical Supply Or Device Loan: $385 · Education: $68.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,384.28 |
| Travel and Lodging | $563.90 |
| Long Term Medical Supply Or Device Loan | $384.93 |
| Education | $68.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $943.75 | 2023-2025 | Minimed 780g, Inceptiv |
| Lilly USA, LLC | $605.51 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $503.43 | 2023-2025 | Freestyle Copilot, Freestyle Libre 3 |
| Amgen INC. | $462.23 | 2023-2025 | Tepezza, Repatha, Otezla |
| Novo Nordisk INC | $404.02 | 2023-2025 | Ozempic, Rybelsus |
| Antares Pharma, INC. | $244.31 | 2023-2024 | Xyosted, Tlando, Nocdurna |
| Abbvie INC. | $199.29 | 2022-2025 | |
| Mannkind Corporation | $139.51 | 2023-2025 | Afrezza |
| Alexion Pharmaceuticals, INC. | $125.22 | 2024-2025 | Strensiq |
| Astrazeneca Pharmaceuticals LP | $97.75 | 2023-2025 | Farxiga, Breztri |
| Dexcom, INC. | $96.28 | 2024-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $91.40 | 2024 | Veozah |
| Janssen Pharmaceuticals, INC | $85.29 | 2021-2022 | |
| Kyowa Kirin, INC. | $65.66 | 2023-2025 | Crysvita |
| Halozyme INC | $60.18 | 2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $57.83 | 2024 | Gvoke Hypopen, Recorlev |
| Horizon Therapeutics Plc | $54.61 | 2023 | Tepezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.39 | 2024-2025 | Jardiance |
| Radius Health, INC. | $41.94 | 2025 | |
| Corcept Therapeutics | $36.28 | 2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $36.05 | 2022 | |
| Ascendis Pharma Endocrinology INC | $24.04 | 2025 | Yorvipath |
| Exact Sciences Corporation | $23.11 | 2023 | Cologuard Collection Kit |
| Rgh Enterprises LLC | $23.11 | 2023 | |
| Glaxosmithkline, LLC. | $20.09 | 2023 | Shingrix |
| Pfizer INC. | $19.66 | 2024 | |
| Lantheus Medical Imaging, INC. | $18.42 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.47 | 2023 | |
| Ibsa Pharma INC. | $16.07 | 2023 | Tirosint, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Staton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.